25 / 32
NMA: improvements in
HRQoL
with AA+P+ADT are
greater than those with D+ADT in patients with HR/HV
mHSPC
Follow-up: LATITUDE – 30.4 months; CHAARTED – unclear
Mean change from baseline in FACT-P total score
1
NMA: improvements in
HRQoL
with AA+P+ADT are
greater than those with D+ADT in patients with HR/HV
mHSPC
Follow-up: LATITUDE – 30.4 months; CHAARTED – unclear
Mean change from baseline in FACT-P total score
1
Feyerabend S et al. Eur J Cancer 2018;doi10.1016/j.ejca.2018.08.
AA, abiraterone acetate; ADT, androgen-deprivation therapy; CrI, credible interval; D, docetaxel; HR, hazard ratio; HRD, high risk
disease; HVD, high volume disease; ITC, indirect treatment comparison; ITT, intent-to-treat; mHSPC, metastatic hormone
sensitive prostate cancer; M1, patients with metastatic disease at randomisation; NDx, newly diagnosed; NMA, network meta-
analysis; P, low-dose prednisone; rPFS, radiographic progression-free survival